| Literature DB >> 29134514 |
Tongmei Zhang1,2, Pei Pang1,2, Zemin Fang3, Yu Guo1,2, Hao Li1,2, Xinyan Li1,2, Tian Tian1,2, Xin Yang1,2, Wenting Chen1,2, Shu Shu1,2, Na Tang1,2, Jianhua Wu1,2, Houze Zhu1,2, Lei Pei2,4, Dan Liu5,6, Qing Tian2,7, Jian Wang2,8, Lin Wang2,8, Ling-Qiang Zhu2,7, Youming Lu9,10.
Abstract
Aggregation of amyloid-β (Aβ) peptides, which are the cleavage products of amyloid precursor protein (APP), is a major pathological hallmark in the brain of Alzheimer's disease (AD). Now, we know little about the roles of APP translation in the disease progression of AD. Here, we show that BC1, a long noncoding RNA (lncRNA), is expressed in the brain of AD mice. BC1 induces APP mRNA translation via association with a fragile X syndrome protein (FMRP). Inhibition of BC1 or BC1-FMRP association in AD mice blocks aggregation of Aβ in the brain and protects against the spatial learning and memory deficits. Expression of exogenous BC1 in excitatory pyramidal neurons of mice induces Aβ peptides accumulation and the spatial learning and memory impairments. This study provides a novel mechanism underlying aggregation of Aβ peptides via BC1 induction of APP mRNA translation and hence warrants a promising target for AD therapy.Entities:
Keywords: Alzheimer’s disease; Amyloid-β peptides; App; BC1; FMRP
Mesh:
Substances:
Year: 2017 PMID: 29134514 DOI: 10.1007/s12035-017-0820-z
Source DB: PubMed Journal: Mol Neurobiol ISSN: 0893-7648 Impact factor: 5.590